Isoliquiritigenin entails blockade of TGF-β1-SMAD signaling for retarding high glucose-induced mesangial matrix accumulation

Journal of Agricultural and Food Chemistry

Volumn 58, Issue 5, 2010, Pages 3205-3212

  Li, Jing ^a,b   Kang, Sang Wook ^a   Kim, Jung Lye ^a   Sung, Hye Young ^a   Kwun, I N Sook ^b   Kang, Young Hee ^a  

^a Hallym University   (South Korea)

^b Andong National University   (South Korea)

Author keywords

High glucose; Isoliquiritigenin; Mesangial matrix; Smad signaling; Tgf

Indexed keywords

CHALCONE DERIVATIVE; GLUCOSE; ISOLIQUIRITIGENIN; PRIMER DNA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MESANGIUM; METABOLISM; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BASE SEQUENCE; CELL LINE; CHALCONES; DNA PRIMERS; GLOMERULAR MESANGIUM; GLUCOSE; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

GLYCYRRHIZA;

EID: 77949421410     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf9040723     Document Type: Article

References (32)

1. Wilkinson-Berka, J. L. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des. 2004, 10, 3331-3348.
2. Schena, F. P.; Gesualdo, L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 2005, 16, S30-S33.
3. Ban, C. R.; Twigg, S. M. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vase. Health Risk Manag. 2008, 4, 575-596.
4. Kanwar, Y. S.; Wada, J.; Sun, L.; Xie, P.; Warmer, E. I.; Chen, S.; Chugh, S.; Danesh, F. R. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood) 2008, 233, 4-11.
5. Ziyadeh, F. N. Mediators of diabetic renal disease: the case for TGFβ as the major mediator. J. Am. Soc. Nephrol. 2004, 15, S55-S57.
6. Mason, R. M. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J. Cell. Commun. Signal. 2009, 3, 95-104.
7. Qi, W.; Chen, X.; Poronnik, P.; Pollock, C. A. Transforming growth factor-β/connective tissue growth factor axis in the kidney. Int. J. Biochem. Cell Biol. 2008, 40, 9-13.
8. Zhou, G.; Li, C.; Cai, L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am. J. Pathol. 2004, 165, 2033-2043.
9. Verrecchia, F.; Mauviel, A.; Farge, D. Transforming growth factor-beta signaling through the SMAD proteins: role in systemic sclerosis. Autoimmun. Rev. 2006, 5, 563-569.
10. Yamabe, N.; Yokozawa, T.; Oya, T.; Kim, M.Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J. Pharmacol. Exp. Ther. 2006, 319, 228-236.
11. Lee, W. C.; Wang, C. J.; Chen, Y. H.; Hsu, J. D.; Cheng, S. Y.; Chen, H. C.; Lee, H. J. Polyphenol extracts from Hibiscus sabdariffa Linnaeus attenuate nephropathy in experimental type 1 diabetes. J. Agric. Food Chem. 2009, 57, 2206-2210.
12. Kamalakkannan, N.; Stanely Mainzen Prince, P. The influence of rutin on the extracellular matrix in streptozotocin-induced diabetic rat kidney. J. Pharm. Pharmacol. 2006, 55, 1091-1098.
13. Li, G. S.; Jiang, W. L.; Yue, X. D.; Qu, G. W.; Tian, J. W.; Wu, J.; Fu, F. H. Effect of Astilbin on experimental diabetic nephropathy in vivo and in vitro. Planta Med. [PMID: 19644810].
14. Kwon, H. M.; Choi, Y. J.; Choi, J. S.; Kang, S. W.; Bae, J. Y.; Kang, I. J.; Jun, J. G.; Lee, S. S.; Lim, S. S.; Kang, Y. H. Blockade of cytokine-induced endothelial cell adhesion molecule expression by licorice isoliquiritigenin through NF-κB signal disruption. Exp. Biol. Med. (Maywood). 2007, 232, 235-245.
15. Yamazaki, S.; Morita, T.; Endo, H.; Hamamoto, T.; Baba, M.; Joichi, Y.; Kaneko, S.; Okada, Y.; Okuyama, T.; Nishino, H.; Tokue, A. Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett. 2002, 183, 23-30.
16. Aida, K.; Tawata, M.; Shindo, H.; Onaya, T.; Sasaki, H.; Yamaguchi, T.; Chin, M.; Mitsuhashi, H. Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. Planta Med. 1990, 56, 254-258.
17. Choi, Y. J.; Lim, S. S.; Jung, J. Y.; Choi, J. S.; Kim, J. K.; Han, S. J.; Kang, Y. H. Blockade of nitroxidative stress by roasted licorice extracts in high glucose-exposed endothelial cells. J. Cardiovasc. Pharmacol. 2008, 52, 344-54.
18. Kim, D. S.; Kwon, H. M.; Choi, J. S.; Kang, S. W.; Ji, G. E.; Kang, Y. H. Resveratrol blunts tumor necrosis factor-α-induced monocyte adhesion and transmigration. Nutr. Res. Pract. 2007, 1, 285-290.
19. Moustakas, A.; Souchelnytskyi, S.; Heldin, C. H. SMAD regulation in TGF-β signal transduction. J. Cell Sci. 2001, 114, 4359-4369.
20. Catania, J. M.; Chen, G.; Parrish, A. R. Role of matrix metalloproteinases in renal pathophysiologies. Am. J. Physiol. 2007, 292, F905-F911.
21. Ji, L.; Yin, X. X.; Wu, Z. M.; Wang, J. Y.; Lu, Q.; Gao, Y. Y. Ginkgo biloba extract prevents glucose-induced accumulation of ECM in rat mesangial cells. Phytother. Res. 2009, 23, 477-485.
22. Luo, P.; Tan, Z.; Zhang, Z.; Li, H.; Mo, Z. Inhibitory effects of salvianolic acid B on the high glucose-induced mesangial proliferation via NF-κB-dependent pathway. Biol. Parm. Bull. 2008, 31, 1381-1386.
23. Zheng, J. M.; Zhu, J. M.; Li, L. S.; Liu, Z. H. Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway. Br. J. Pharmacol. 2008, 153, 1456-1464.
24. Asl, M. N.; Hosseinzadeh, H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother. Res. 2008, 22, 709-724.
25. Zhou, G.; Li, C.; Cai, L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am. J. Pathol. 2004, 165, 2033-2043.
26. Berrou, J.; Tostivint, I.; Verrecchia, F.; Berthier, C.; Boulanger, E.; Mauviel, A.; Marti, H. P.; Wautier, M. P.; Wautier, J. L.; Rondeau, E.; Hertig, A. Advanced glycation end products regulate extra-cellular matrix protein and protease expression by human glomerular mesangial cells. Int. J. Mol. Med. 2009, 23, 513-520.
27. Wu, D.; Peng, F.; Zhang, B.; Ingram, A. J.; Kelly, D. J. PKC-β1 mediates glucose-induced Akt activation and TGF-β1 upregulation in mesangial cells. J. Am. Soc. Nephrol. 2009, 20, 554-566.
28. Huang, P.; Zhang, Y.; Jiang, T.; Zeng, W.; Zhang, N. Aldose reductase is a potent regulator of TGF-β1 induced expression of flbronectin in human mesangial cells. Mol. Biol. Rep. [PMID: 19847669].
29. Muthenna, P.; Suryanarayana, P.; Gunda, S. K.; Petrash, J. M.; Reddy G. B. Inhibition of aldose reductase by dietary antioxidant curcumin: Mechanism of inhibition, specificity and significance. FEBS Lett. [PMID: 19850041].
30. Qian, Y.; Feldman, E.; Pennathur, S.; Kretzler, M.; Brosius, F. C.3rd From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008, 57, 1439-1445.
31. Tesch, G. H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. 2008, 294, F697-F701.
32. Li, J. J.; Lee, S. H.; Kim, D. K.; Jin, R.; Jung, D. S. Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy. Am. J. Physiol. 2009, 297, F200-F209.